Kimelman & Baird LLC Takes $895,000 Position in Bristol Myers Squibb Company $BMY

Key Points

• Kimelman & Baird LLC purchased 15,525 Bristol Myers Squibb shares worth approximately $895,000 during the second quarter. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported quarterly earnings of $2.04 per share and revenue of $12.97 billion, beating analyst estimates, while setting fiscal 2026 EPS guidance of $6.75–$7.00.
• The FDA approved Zenbexus for relapsed or refractory multiple myeloma, providing a potential oncology growth driver, but competitive pressure on Camzyos and the end of BMY’s Cellares partnership create risks for its cardiovascular and cell-therapy businesses.

Kimelman & Baird LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 15,525 shares of the biopharmaceutical company's stock, valued at approximately $895,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Davis Asset Management L.P. purchased a new stake in Bristol Myers Squibb in the second quarter worth $27,000. Swiss RE Ltd. purchased a new position in Bristol Myers Squibb during the fourth quarter valued at $25,000. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb during the second quarter valued at $25,000. Addison Advisors LLC bought a new stake in Bristol Myers Squibb in the second quarter worth $32,000. Finally, Bayban bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at $31,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
• Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
• Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
• Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
• Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares

Bristol Myers Squibb Stock Down 0.5%

BMY opened at $66.62 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm's fifty day moving average is $61.76 and its 200 day moving average is $59.68. The stock has a market cap of $136.09 billion, a price-to-earnings ratio of 14.67, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company's quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.05% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BMY. Bank of America dropped their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating on the stock in a research note on Friday, July 10th. UBS Group cut shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. Wells Fargo & Company set a $65.00 target price on shares of Bristol Myers Squibb and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Wall Street Zen upgraded shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 27th. Finally, TD Cowen started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "buy" rating for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.